Morphological and growth altering effects of Cisplatin in C. albicans using fluorescence microscopy
Chandrasekhar Kesavan¹, Malathi Raghunathan² and Natarajan Ganesan*³

Abstract
Changes in morphology and growth curve of Candida albicans in response to treatment by Cisplatin has been studied using fluorescence staining with ethidium bromide. Treatment with Cisplatin was found to markedly inhibit hyphae and ovoid growth as revealed by ethidium bromide staining of drug treated cells. These changes were concomitant with inhibitory effects on the growth curve with respect to untreated cells.

Presence of Cisplatin not only caused suppression in the limiting values in the growth curve, but also caused a slight left shift in the EC50 values. Some of the ovoid cells undergoing poisoning with cisplatin were found to be unusually enlarged before undergoing their natural fate thus suggesting formation of similar cytotoxic end products with DNA.

Introduction
Candida albicans is a yeast pathogen that causes mild, chronic, superficial systemic infections in immunocompromised and cancer patients [1-3]. Research, worldwide is broadly focused on 1) search of new targets in C. albicans, 2) Screening inhibitory activities with therapeutic agents, and 3) designing or modifying novel agents, to overcome treatment resistance [4]. C. albicans has been shown to harbor a self splicing group-I intron in the nuclear 25s rRNA genes [5]. Presence of this gene in C. albicans, but not in the human genome, suggests that splicing inhibitors could potentially act as alternate targets in controlling the proliferation of fungal pathogens. Recent screening studies using disk diffusion have shown that cis-diamminedichloro platinum (Cisplatin), a well-established antitumor agent, inhibits the growth of C. albicans at lower concentrations [6]. Despite its prevalent use in cancer treatment, very little work has been done [7-10] to document the effects of Cisplatin and related metal complexes in controlling the proliferation behavior of C. albicans. With the molecular mechanisms remaining largely unknown, this provided us a basis to study the effects of Cisplatin treatment on the morphology and growth curve of C. albicans. Morphological changes in Candida can be followed by direct fluorescence staining with suitable dyes to selectively visualize different parts/aspects of cellular activities [11-13]. Though the use of Ethidium Bromide for fluorescence staining is well known, there is no report to show the use of this technique in studying the morphology of Candida, especially in response to treatment with anticancer agents such as Cisplatin. Herein, we report the morphological changes of C. albicans in response to cisplatin using fluorescence microscopy with ethidium bromide staining.
Materials and methods

Media and Inoculums

Yeast isolates (clinical strains) were obtained from patients, Royapettah Hospital, Chennai. Sub-cultured isolates were maintained in Sabouraud dextrose agar (B.B.L, Cockeysville, MD) at 1–5 × 10^6 CFU/10 ml media. 30 µl of each sample (log phase) was used for slide preparation to study the morphological changes.

Drug preparation

A 2 mg/ml stock of Cisplatin (TNDPL, Chennai) was prepared in sterile Millipore water. Stock was diluted to 60 µg/10 ml culture for treatment purposes.

Staining

Ethidium bromide staining was performed using a freshly prepared stock of ethidium bromide (1 mg/ml water) from which 50 µl/100 ml concentration was used for staining the slides. Gram staining was performed from commercially available kits as per instructions.

Morphological studies using Fluorescence Microscopy

30 µl of cultured C. albicans (Drug treated/non-treated cells) was taken and spread over the clean glass slide and dried at 37°C for 5 minutes. Slides were dipped into the EtBr staining solution for 30–40 seconds followed by immersion in water for 15–20 seconds to remove excess stain. Gram staining was performed in parallel on a similar set of slides to validate the results. Both the set of slides were viewed using NFM under the 100× magnification.

Results and Discussion

Treatment of C. albicans with Cisplatin was found to markedly inhibit hyphae and ovoid growth (Fig. 2) as revealed by ethidium bromide staining of drug treated cells. This was in contrast to the controls showing markedly branched hyphae, with budding characteristics.

Figure 1

Photograph showing morphology of Candida albicans in the absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain.
1) The ovoid cells of Cisplatin treated *C. albicans* showed an increased uptake of the ethidium bromide stain (red color) in contrast to the untreated counterparts (yellowish orange), thus pointing to drug induced poisoning and death of treated cells. These changes were concomitant with inhibitory effects on the growth curve with respect to untreated cells (Fig. 3). Presence of Cisplatin not only caused suppression in the limiting growth values but caused a slight left shift in the EC50 values, which remains to be studied further. Some of the ovoid cells undergoing poisoning with cisplatin were found to be unusually enlarged before undergoing their natural fate (Fig. 2). This is known to be one of the typical effects of poisoning with cisplatin in case of tumor cell lines as well thus suggesting formation of similar cytotoxic end products [14]. Cisplatin in water forms a diaqua species of Pt^{2+} due to the fast leaving Cl^- ions. This could lead further to host of reactions in the cytoplasm before forming end products with DNA. It is also possible that cisplatin exerts its activity through other secondary response mechanisms. Further studies using RT-PCR will elucidate 1) the role of the

**Figure 2**
Photograph showing morphology of *Candida albicans* in the presence or absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain.

**Figure 3**
Growth curve of *Candida albicans* in the presence/absence of Cisplatin (6 µg/ml). Curve fitting of data points was performed using non-linear regression(sigmoidal curve): GraphPad Prism Version 3.02.
binding affinity of cis-DDP to certain RNA species in cytotoxicity against *C. albicans*, for example, group-I intron ribozyme, known in many human diseases causing pathogens and a potential target site for therapeutic agents. 2) Whether cis-DDP inhibits the *C. albicans* growth through penetration into the cell or some secondary response.

**Acknowledgements**

K.C thanks the Lady Tata Memorial Trust for the fellowship in pursuing this research work.

**References**

1. Calderone RA, Fonzi WA: Virulence factors of Candida albicans. Trends Microbiol 2001, 9:327-335.
2. Wall SD, Jones B: Gastrointestinal tract in the immunocompromised host: opportunistic infections and other complications. Radiology 1992, 185:327-335.
3. Saral R: Candida and Aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis 1991, 13:487-492.
4. St GV: Membrane transporters and antifungal drug resistance. Curr Drug Targets 2000, 1:261-284.
5. Miletic KE, Leibowicz MJ: Pentamidine inhibition of group I intron splicing in *Candida albicans* correlates with growth inhibition. Antimicrob Agents Chemother 2000, 44:958-966.
6. Chandrasekar K, Shyla JH, Malashi R: Can antitumor platinum compounds be effective against *Candida albicans*?--A screening assay using disk diffusion method. J Clin Microbiol 2000, 38:3905.
7. Watanabe T, Takano M, Ogasawara A, Mikami T, Kobayashi T, Watabe M, Matsumoto T: Anti-Candida activity of a new platinum derivative. Antimicrob Agents Chemother 2000, 44:2853-2854.
8. Sarachek A, Henderson L, Wilkens WE: Evaluation of the genotoxic spectrum of cisplatin for *Candida albicans*. Microbes 1992, 72:183-201.
9. Sarachek A, Henderson LA: Modification of responses of *Candida albicans* to cisplatin by membrane damaging antifungal agents. Mycoses 1991, 34:177-182.
10. Mousa NM, Ghannoun MA, Whitaker PA, el Ezaby MS, Quraman S: Effects of cisplatin and two novel palladium complexes on *Candida albicans*. Microbios 1990, 62:165-178.
11. Bernhardt H, Knoke M, Bernhardt J: Changes in *Candida albicans* colonization and morphology under influence of voriconazole. Mycoses 2003, 46:370-374.
12. Hopfer RL, Sparks SD, Cox GM: The use of flow cytometry as a tool for monitoring filament formation of fungi. Med Mycol 2001, 39:103-107.
13. Aoki S, Ito-Kuwa S, Nakamura Y, Masuhara T: Mitochondrial behaviour during the yeast-hypha transition of *Candida albicans*. Microbes 1989, 60:79-86.
14. Otto AM, Paddenberg R, Schubert S, Mannherz HG: Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996, 122:603-612.